Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Uterine Neoplasms 1 Uterine Diseases 1 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Uterine Cervical Diseases 1 Urogenital Neoplasms 1 Urogenital Diseases 1 Precancerous Conditions 1 Neoplasms by Site 1 Neoplasms 1 Lung Neoplasms 1 Genital Neoplasms, Female 1 Genital Diseases, Female 1 Genital Diseases 1 Female Urogenital Diseases and Pregnancy Complications 1

Interventions

pembrolizumab 49 Carboplatin 44 Magnetic Resonance Spectroscopy 40 Specimen Handling 39 Pemetrexed 34 Cisplatin 25 Blood Specimen Collection 25 durvalumab 17 Paclitaxel 16 osimertinib 15 Radiotherapy 15 Radiosurgery 15 Bevacizumab 15 Gemcitabine 14 atezolizumab 13 Nivolumab 13 Biopsy 13 Drug Therapy 12 Standard of Care 10 Practice Guidelines as Topic 10 Immunoglobulin G 10 Docetaxel 10 130-nm albumin-bound paclitaxel 10 X-Rays 9 Taxes 9 Educational Status 9 Disulfides 9 tislelizumab 8 Etoposide 8 Cetuximab 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Lung Neoplasms × Pregnancy Tests × Clear all

NCT06620835 2026-04-29

OPTALK

Groupe Francais De Pneumo-Cancerologie

Phase 2 Recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡